Lapatinib-based therapy for women with advanced/metastatic HER2 positive breast cancer
Background: Lapatinib alone or in combination with other agents, mostly capecitabine is used for patients with advanced/metastatic HER2 positive breast cancer (HER2+BC) after progression on trastuzumab based therapy. Here we report our experience with lapatinib based therapy in this setting. Materia...
Збережено в:
| Опубліковано в: : | Experimental Oncology |
|---|---|
| Дата: | 2015 |
| Автори: | , , , , , , , , |
| Формат: | Стаття |
| Мова: | Англійська |
| Опубліковано: |
Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
2015
|
| Теми: | |
| Онлайн доступ: | https://nasplib.isofts.kiev.ua/handle/123456789/145471 |
| Теги: |
Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|
| Назва журналу: | Digital Library of Periodicals of National Academy of Sciences of Ukraine |
| Цитувати: | Lapatinib-based therapy for women with advanced/metastatic HER2 positive breast cancer / J. Zekri, M. Mokhtar, S.M. Karim, T. Darwish, M. Al-Foheidi, A. Rizvi, S. Al-Rehaily, M. Mahrous, M. Mansour // Experimental Oncology. — 2015. — Т. 37, № 2. — С. 146-150. — Бібліогр.: 24 назв. — англ. |
Репозитарії
Digital Library of Periodicals of National Academy of Sciences of Ukraine| _version_ | 1862716592633151488 |
|---|---|
| author | Zekri, J. Mokhtar, M. Karim, S.M. Darwish, T. Al-Foheidi, M. Rizvi, A. Al-Rehaily, S. Mahrous, M. Mansour, M. |
| author_facet | Zekri, J. Mokhtar, M. Karim, S.M. Darwish, T. Al-Foheidi, M. Rizvi, A. Al-Rehaily, S. Mahrous, M. Mansour, M. |
| citation_txt | Lapatinib-based therapy for women with advanced/metastatic HER2 positive breast cancer / J. Zekri, M. Mokhtar, S.M. Karim, T. Darwish, M. Al-Foheidi, A. Rizvi, S. Al-Rehaily, M. Mahrous, M. Mansour // Experimental Oncology. — 2015. — Т. 37, № 2. — С. 146-150. — Бібліогр.: 24 назв. — англ. |
| collection | DSpace DC |
| container_title | Experimental Oncology |
| description | Background: Lapatinib alone or in combination with other agents, mostly capecitabine is used for patients with advanced/metastatic HER2 positive breast cancer (HER2+BC) after progression on trastuzumab based therapy. Here we report our experience with lapatinib based therapy in this setting. Material and Methods: 67 consecutive patients received lapatinib based therapy. 58 (86.6%) received lapatinib + capecitabine (LC), 7 (10.4%) with other agents and 2 (3.0%) as single agent lapatinib. Data was collected from patients’ records retrospectively. Results: Objective response to lapatinib based therapy in 64 evaluable patients was 64.0% in all patients and 64.0% in patients who received LC. Median progression free survival and overall survival were 10 and 27 months in all patients and 10 and 17 months in patients who received LC, respectively. 16 (24.0%) patients had dose delay > 1 week and/or dose reduction. Conclusion: Lapatinib based therapy is an effective treatment for women with advanced/metastatic HER2+BC after prior exposure to trastuzumab. It yields meaningful response rates, progression free and overall survival. Some patients require dose adjustments. Key Words: lapatinib-based therapy, metastatic breast cancer, HER2 positive breast cancer, trastuzumab.
|
| first_indexed | 2025-12-07T18:06:55Z |
| format | Article |
| fulltext | |
| id | nasplib_isofts_kiev_ua-123456789-145471 |
| institution | Digital Library of Periodicals of National Academy of Sciences of Ukraine |
| issn | 1812-9269 |
| language | English |
| last_indexed | 2025-12-07T18:06:55Z |
| publishDate | 2015 |
| publisher | Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України |
| record_format | dspace |
| spelling | Zekri, J. Mokhtar, M. Karim, S.M. Darwish, T. Al-Foheidi, M. Rizvi, A. Al-Rehaily, S. Mahrous, M. Mansour, M. 2019-01-22T11:38:03Z 2019-01-22T11:38:03Z 2015 Lapatinib-based therapy for women with advanced/metastatic HER2 positive breast cancer / J. Zekri, M. Mokhtar, S.M. Karim, T. Darwish, M. Al-Foheidi, A. Rizvi, S. Al-Rehaily, M. Mahrous, M. Mansour // Experimental Oncology. — 2015. — Т. 37, № 2. — С. 146-150. — Бібліогр.: 24 назв. — англ. 1812-9269 https://nasplib.isofts.kiev.ua/handle/123456789/145471 Background: Lapatinib alone or in combination with other agents, mostly capecitabine is used for patients with advanced/metastatic HER2 positive breast cancer (HER2+BC) after progression on trastuzumab based therapy. Here we report our experience with lapatinib based therapy in this setting. Material and Methods: 67 consecutive patients received lapatinib based therapy. 58 (86.6%) received lapatinib + capecitabine (LC), 7 (10.4%) with other agents and 2 (3.0%) as single agent lapatinib. Data was collected from patients’ records retrospectively. Results: Objective response to lapatinib based therapy in 64 evaluable patients was 64.0% in all patients and 64.0% in patients who received LC. Median progression free survival and overall survival were 10 and 27 months in all patients and 10 and 17 months in patients who received LC, respectively. 16 (24.0%) patients had dose delay > 1 week and/or dose reduction. Conclusion: Lapatinib based therapy is an effective treatment for women with advanced/metastatic HER2+BC after prior exposure to trastuzumab. It yields meaningful response rates, progression free and overall survival. Some patients require dose adjustments. Key Words: lapatinib-based therapy, metastatic breast cancer, HER2 positive breast cancer, trastuzumab. en Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України Experimental Oncology Original contributions Lapatinib-based therapy for women with advanced/metastatic HER2 positive breast cancer Article published earlier |
| spellingShingle | Lapatinib-based therapy for women with advanced/metastatic HER2 positive breast cancer Zekri, J. Mokhtar, M. Karim, S.M. Darwish, T. Al-Foheidi, M. Rizvi, A. Al-Rehaily, S. Mahrous, M. Mansour, M. Original contributions |
| title | Lapatinib-based therapy for women with advanced/metastatic HER2 positive breast cancer |
| title_full | Lapatinib-based therapy for women with advanced/metastatic HER2 positive breast cancer |
| title_fullStr | Lapatinib-based therapy for women with advanced/metastatic HER2 positive breast cancer |
| title_full_unstemmed | Lapatinib-based therapy for women with advanced/metastatic HER2 positive breast cancer |
| title_short | Lapatinib-based therapy for women with advanced/metastatic HER2 positive breast cancer |
| title_sort | lapatinib-based therapy for women with advanced/metastatic her2 positive breast cancer |
| topic | Original contributions |
| topic_facet | Original contributions |
| url | https://nasplib.isofts.kiev.ua/handle/123456789/145471 |
| work_keys_str_mv | AT zekrij lapatinibbasedtherapyforwomenwithadvancedmetastaticher2positivebreastcancer AT mokhtarm lapatinibbasedtherapyforwomenwithadvancedmetastaticher2positivebreastcancer AT karimsm lapatinibbasedtherapyforwomenwithadvancedmetastaticher2positivebreastcancer AT darwisht lapatinibbasedtherapyforwomenwithadvancedmetastaticher2positivebreastcancer AT alfoheidim lapatinibbasedtherapyforwomenwithadvancedmetastaticher2positivebreastcancer AT rizvia lapatinibbasedtherapyforwomenwithadvancedmetastaticher2positivebreastcancer AT alrehailys lapatinibbasedtherapyforwomenwithadvancedmetastaticher2positivebreastcancer AT mahrousm lapatinibbasedtherapyforwomenwithadvancedmetastaticher2positivebreastcancer AT mansourm lapatinibbasedtherapyforwomenwithadvancedmetastaticher2positivebreastcancer |